Contrast-enhanced subtraction harmonic sonography for evaluating treatment response in patients with hepatocellular carcinoma.

OBJECTIVE Our objective was to assess the usefulness of contrast-enhanced subtraction harmonic sonography in evaluating the treatment response of patients with hepatocellular carcinoma. SUBJECTS AND METHODS Thirty-two hepatocellular carcinoma lesions in 26 patients (age range, 44-85 years; mean age, 66 years) were examined with Levovist-enhanced intermittent harmonic imaging before and after therapy. A Toshiba Powervision 8000 was used. A subtraction image was obtained by digitally subtracting the last-frame harmonic image from the first-frame image when multishot mode was preset. Results of contrast-enhanced CT were compared with the results of subtraction harmonic imaging. RESULTS Before therapy, an enhancement pattern of tumor vascularity was seen for 93.8% (30/32) of hepatocellular carcinoma nodules on subtraction harmonic imaging. After therapy, subtraction harmonic imaging showed 46.7% (14/30) enhancement (incomplete tumor necrosis) and 53.3% (16/30) no enhancement (complete tumor necrosis). When dynamic CT was the gold standard, the sensitivity, specificity, and accuracy of subtraction harmonic imaging were 93.3%, 100%, and 96.7%, respectively. Intratumoral flow signals in hepatocellular carcinoma after therapy on harmonic imaging were used as a guide to target additional percutaneous therapy. CONCLUSION Digital subtraction contrast-enhanced harmonic imaging can depict tumor vascularity in hepatocellular carcinoma after therapy sensitively and accurately. Because it is easy to perform and provides real-time needle insertion guidance, it may be preferable to perform after localized therapy to monitor treatment response, which will reduce unnecessary CT scanning.

[1]  O. Matsui,et al.  Progression to hypervascular hepatocellular carcinoma: correlation with intranodular blood supply evaluated with CT during intraarterial injection of contrast material. , 2002, Radiology.

[2]  D. Bluemke,et al.  Imaging evaluation of hepatocellular carcinoma. , 2002, Journal of Vascular and Interventional Radiology.

[3]  G. Dodd,et al.  Sonographically observed echogenic response during intraoperative radiofrequency ablation of cirrhotic livers: pathologic correlation. , 2002, AJR. American journal of roentgenology.

[4]  L Solbiati,et al.  Essential techniques for successful radio-frequency thermal ablation of malignant hepatic tumors. , 2001, Radiographics : a review publication of the Radiological Society of North America, Inc.

[5]  Y. Shiratori,et al.  Management of hepatocellular carcinoma: advances in diagnosis, treatment and prevention , 2001, Expert review of anticancer therapy.

[6]  P. Burns,et al.  Harmonic hepatic US with microbubble contrast agent: initial experience showing improved characterization of hemangioma, hepatocellular carcinoma, and metastasis. , 2000, Radiology.

[7]  B. Choi,et al.  Vascularity of hepatocellular carcinoma: assessment with contrast-enhanced second-harmonic versus conventional power Doppler US. , 2000, Radiology.

[8]  G S Gazelle,et al.  Radio-frequency-induced coagulation necrosis in rabbits: immediate detection at US with a synthetic microsphere contrast agent. , 1999, Radiology.

[9]  L Solbiati,et al.  Radio-frequency ablation of hepatic metastases: postprocedural assessment with a US microbubble contrast agent--early experience. , 1999, Radiology.

[10]  H. Dittrich,et al.  Evaluation of myocardial, hepatic, and renal perfusion in a variety of clinical conditions using an intravenous ultrasound contrast agent (Optison) and second harmonic imaging , 1999, Heart.

[11]  F. Moriyasu,et al.  Analysis of flash echo from contrast agent for designing optimal ultrasound diagnostic systems. , 1999, Ultrasound in medicine & biology.

[12]  H. Yamamoto,et al.  Power Doppler sonography assessment of tumor recurrence after chemoembolization therapy for hepatocellular carcinoma. , 1999, AJR. American journal of roentgenology.

[13]  A Paolicchi,et al.  Hepatocellular carcinoma treatment with percutaneous ethanol injection: evaluation with contrast-enhanced color Doppler US. , 1998, Radiology.

[14]  B. Choi,et al.  Hepatocellular carcinoma: power Doppler US with a contrast agent--preliminary results. , 1998, Radiology.

[15]  R. Lagalla,et al.  Monitoring treatment response with color and power Doppler. , 1998, European journal of radiology.

[16]  L Solbiati,et al.  Ablation of liver tumors using percutaneous RF therapy. , 1998, AJR. American journal of roentgenology.

[17]  M. Mitomo,et al.  Visualization of tumor vessels in hepatocellular carcinoma , 1997, Acta radiologica.

[18]  Y. Kono,et al.  Gray-scale second harmonic imaging of the liver with galactose-based microbubbles. , 1997, Investigative radiology.

[19]  R Fiocca,et al.  Percutaneous US-guided radio-frequency tissue ablation of liver metastases: treatment and follow-up in 16 patients. , 1997, Radiology.

[20]  P. Burns.  Harmonic imaging with ultrasound contrast agents. , 1996, Clinical radiology.

[21]  E. G. Hahn,et al.  Color Doppler ultrasound of liver lesions: Signal enhancement after intravenous injection of the ultrasound contrast agent Levovist® , 1996, Journal of clinical ultrasound : JCU.

[22]  H. D’Agostino,et al.  Percutaneous ablation therapy for hepatocellular carcinomas. , 1995, AJR. American journal of roentgenology.

[23]  M Takahashi,et al.  Treatment of hepatocellular carcinoma: value of percutaneous microwave coagulation. , 1995, AJR. American journal of roentgenology.

[24]  C. Bartolozzi,et al.  Hepatocellular carcinoma: use of color Doppler US to evaluate response to treatment with percutaneous ethanol injection. , 1995, Radiology.

[25]  C. Bartolozzi,et al.  Hepatocellular carcinoma: CT and MR features after transcatheter arterial embolization and percutaneous ethanol injection. , 1994, Radiology.

[26]  C. McArdle,et al.  Improved sensitivity of colour Doppler flow imaging of colorectal hepatic metastases using galactose microparticles: A preliminary report , 1994, The British journal of surgery.

[27]  H. Okazaki,et al.  Hepatocellular carcinoma: treatment with percutaneous ethanol injection and transcatheter arterial embolization. , 1992, Radiology.

[28]  S. Takebayashi,et al.  Color Doppler sonography of hepatocellular carcinoma before and after treatment by transcatheter arterial embolization. , 1992, AJR. American journal of roentgenology.

[29]  Y. I. Kim,et al.  Therapeutic effect of transcatheter oily chemoembolization therapy for encapsulated nodular hepatocellular carcinoma: CT and pathologic findings. , 1992, Radiology.

[30]  M. Fujita,et al.  Small hepatocellular carcinoma: differentiation from adenomatous hyperplastic nodule with color Doppler flow imaging. , 1992, Radiology.

[31]  Katsuaki Tanaka,et al.  Hepatocellular carcinoma: treatment with a combination therapy of transcatheter arterial embolization and percutaneous ethanol injection. , 1991, Radiology.

[32]  K J Parker,et al.  Contrast agents in diagnostic ultrasound. , 1989, Ultrasound in medicine & biology.

[33]  J. Okamura,et al.  Transcatheter chemo‐embolization effective for treating hepatocellular carcinoma. A histopathologic study , 1984, Cancer.